00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
22:00 , Aug 9, 2018 |  BC Extra  |  Politics & Policy

China releases list of overseas drugs eligible for Priority Review

China’s Drug Evaluation Center posted a list of 48 drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China. Last December, China's State Drug Administration released guidance to...
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
15:28 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves Agios' IDH1 inhibitor Tibsovo for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat relapsed or refractory acute myelogenous leukemia (AML) in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first FDA-approved...
16:44 , Jul 20, 2018 |  BC Extra  |  Company News

FDA approves Agios' IDH1 inhibitor for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) on Friday to treat relapsed or refractory acute myelogenous leukemia in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first...
17:33 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest vaccines based on R123H-mutant IDH1 could help treat sarcomas harboring the mutation. In a syngeneic mouse model of sarcoma expressing the IDH1 R132H mutation, vaccination with a R132H-mutant IDH1 peptide decreased...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
15:00 , Jun 29, 2018 |  BC Week In Review  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies. Agios...